Beta Bionics Inc. (BBNX) Next Earnings Date & Expected ±12.5% Move

BBNX scores 39 out of 100 with a letter grade of D- and the verdict label "Roarable Sell — Vulnerable Balance Sheet & Flow." Across the five pillars:

• Fundamental Cash Engine: 9 / 20. ROIC is -22.1% and FCF yield is -5.88%. For a prospective investor, this means the business is not currently converting capital into positive returns or free cash flow, so any valuation case must rest on future earnings expansion rather than current cash generation.
• Whale 13F Flow: 9 / 20. this pillar reflects institutional accumulation and options positioning. The score is below midpoint, indicating limited institutional conviction in the source data.
• Insider Conviction: 3 / 20. this is the lowest pillar and reflects SEC Form 4 and Congressional PTR cluster flow. A low score here signals weak insider-side confidence as measured by the rating model.
• Macro Regime Fit: 7 / 20. beta is 1.0 with sector sensitivity considered. The stock's market-level volatility is in line with the broad market, but the pillar score reflects limited alignment with the current regime.
• Forensic Balance Sheet: 11 / 20. Altman Z is 12.82, Piotroski F is 4/9, and Debt/Equity is 0.5. This is the strongest pillar, indicating a relatively stronger balance sheet position than the other pillars, though the Piotroski score sits below the midpoint.

Taken together, the rating points to a business with a comparatively sturdy balance sheet but weak operating returns, negative cash flow, and thin insider and institutional support. Valuation tradeoffs are significant given the negative margins noted in the market data.

. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Medical/Dental Instruments industry. Per the market data, the company reports a gross margin of 55.4%. — for detailed product lines, customer segments, or revenue model descriptions.

Revenue rose from $12.0M in FY 2023 to $100.3M in FY 2025, while operating losses and free cash flow outflows widened over the same span. Per the market data, operating margin and net margin are both -60%. ROIC is -22.1%, Altman Z-Score is 12.82, and Piotroski F-Score is 4/9. Debt/Equity is 0.5; the debt line item is — for the reported periods.

• 🐂 Primary Bull Case: Revenue scaled from $12.0M in FY 2023 to $100.3M in FY 2025 while the forensic balance sheet scored 11 / 20 with an Altman Z of 12.82. With Fundamental Cash Engine at 9/20 (ROIC -22.1%, FCF yield -5.88%) and Institutional Whale Flow at 6/20, sustained execution supports upside toward the top of the $8.80 – $32.71 52-week range.
• 🐻 Primary Bear Case: Operating margin of -60% and FCF of -$56.2M in FY 2025, with ROIC at -22.1% and Insider Conviction scored 3 / 20. Investors must weigh current valuation against -60.0% operating margins and a 1.00 macro beta if sector demand softens.

There are no upstream or downstream links and no proprietary signals recorded. Sector correlations and second-order bottlenecks are — Investors should note that the class action items in the news feed are the only cross-cutting event signals present in the source data.

• Key Question #1: What are the forward earnings and cash-flow estimates, given that analyst data is absent and forward P/E is unavailable?
• Key Question #2: What is the company's debt schedule and cash runway, since the debt line item is —?
• Key Question #3: What is the scope and merit of the securities class action referenced in the news feed?